Lee H, Hwang M, Jang S, Um S. Immune Regulatory Function of Cancer- Associated Fibroblasts in Non-small Cell Lung Cancer. Tuberc Respir Dis (Seoul). 2023;86:304-318 pubmed publisher

Balasko A, Kowatsch M, Graydon C, Lajoie J, Fowke K. The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function. Sci Rep. 2023;13:10082 pubmed publisher

Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, et al. BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression. J Immunother Cancer. 2022;10: pubmed publisher

Takele Y, Adem E, Franssen S, Womersley R, Kaforou M, Levin M, et al. Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation. PLoS Negl Trop Dis. 2022;16:e0010544 pubmed publisher

Thakkar D, Paliwal S, Dharmadhikari B, Guan S, Liu L, Kar S, et al. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. J Immunother Cancer. 2022;10: pubmed publisher

Assi H, Wong C, Tipton K, Mei L, Wong K, Razo J, et al. Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. Cancer Immunol Res. 2021;9:1451-1464 pubmed publisher

Phakham T, Bulaon C, Khorattanakulchai N, Shanmugaraj B, Buranapraditkun S, Boonkrai C, et al. Functional Characterization of Pembrolizumab Produced in Nicotiana benthamiana Using a Rapid Transient Expression System. Front Plant Sci. 2021;12:736299 pubmed publisher

Tahir S, Bourquard T, Musnier A, Jullian Y, Corde Y, Omahdi Z, et al. Accurate determination of epitope for antibodies with unknown 3D structures. MAbs. 2021;13:1961349 pubmed publisher

Junker F, Gulati P, Wessels U, Seeber S, Stubenrauch K, Codarri Deak L, et al. A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. Cytometry A. 2021;99:832-843 pubmed publisher

Roberts A, Bentley L, Tang T, Stewart F, Pallini C, Juvvanapudi J, et al. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. Sci Rep. 2021;11:4030 pubmed publisher

Fassler M, Rappaport M, Cuño C, George J. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer's disease models. J Neuroinflammation. 2021;18:19 pubmed publisher

Smalley M, Przedborski M, Thiyagarajan S, Pellowe M, Verma A, Brijwani N, et al. Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics. iScience. 2020;23:101229 pubmed publisher

Sasaki T, Yajima T, Shimaoka T, Ogawa S, Saito T, Yamaoka K, et al. Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. Int Immunol. 2020;32:163-174 pubmed publisher